{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:57:33Z","timestamp":1776329853157,"version":"3.50.1"},"reference-count":32,"publisher":"Baskent University","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.6002\/ect.mesot2018.o58","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T07:49:33Z","timestamp":1550562573000},"page":"113-119","source":"Crossref","is-referenced-by-count":3,"title":["Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience"],"prefix":"10.6002","volume":"17","author":[{"name":"the Kuwait Ministry of Health, Hamed Al-Essa Organ Transplant Center, Sabah Area, Kuwait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Gheith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torki","family":"Al-Otaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzann","family":"Rida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat A.","family":"Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdul-Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Emam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"issue":"2","key":"ref0","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellares","year":"2012","unstructured":"1.\tSellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-399.","journal-title":"Am J Transplant"},{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss","volume":"9","author":"El-Zoghby","year":"2009","unstructured":"2.\tEl-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-535.","journal-title":"Am J Transplant"},{"issue":"9","key":"ref2","doi-asserted-by":"publisher","first-page":"e0162278","DOI":"10.1371\/journal.pone.0162278","article-title":"The spectrum of renal allograft failure.","volume":"11","author":"Chand","year":"2016","unstructured":"3.\tChand S, Atkinson D, Collins C, et al. The spectrum of renal allograft failure. PLoS One. 2016;11(9):e0162278.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/TP.0000000000001648","article-title":"Clinical trials for immunosuppression in transplantation: the case for reform and change in direction","volume":"101","author":"O'Connell","year":"2017","unstructured":"4.\tO'Connell PJ, Kuypers DR, Mannon RB, et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction. Transplantation. 2017;101(7):1527-1534.","journal-title":"Transplantation"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","article-title":"Transplant glomerulopathy: subclinical incidence and association with alloantibody","volume":"7","author":"Gloor","year":"2007","unstructured":"5.\tGloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant. 2007;7(9):2124-2132.","journal-title":"Am J Transplant"},{"issue":"7","key":"ref5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts","volume":"26","author":"Loupy","year":"2015","unstructured":"6.\tLoupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol. 2015;26(7):1721-1731.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')","volume":"7","author":"Solez","year":"2007","unstructured":"7.\tSolez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7(3):518-526.","journal-title":"Am J Transplant"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy","volume":"80","author":"Baid-Agrawal","year":"2011","unstructured":"8.\tBaid-Agrawal S, Farris AB, 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int. 2011;80(8):879-885.","journal-title":"Kidney Int"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1681\/ASN.2010111183","article-title":"Antibodies reactive to non-HLA antigens in transplant glomerulopathy","volume":"22","author":"Dinavahi","year":"2011","unstructured":"9.\tDinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol. 2011;22(6):1168-1178.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/ctr.12433","article-title":"Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection","volume":"28","author":"Torres","year":"2014","unstructured":"10.\tTorres IB, Salcedo M, Moreso F, et al. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Clin Transplant. 2014;28(10):1148-1154.","journal-title":"Clin Transplant"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/TP.0000000000000310","article-title":"Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy","volume":"99","author":"Lesage","year":"2015","unstructured":"11.\tLesage J, Noel R, Lapointe I, et al. Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation. 2015;99(1):69-76.","journal-title":"Transplantation"},{"issue":"2","key":"ref11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","unstructured":"12.\tDjamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14(2):255-271.","journal-title":"Am J Transplant"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","unstructured":"13.\tCornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant. 2015;15(5):1293-1302.","journal-title":"Am J Transplant"},{"issue":"9","key":"ref13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/TP.0b013e3181880b35","article-title":"Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients","volume":"86","author":"Billing","year":"2008","unstructured":"14.\tBilling H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation. 2008;86(9):1214-1221.","journal-title":"Transplantation"},{"issue":"12","key":"ref14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1097\/TP.0b013e3181a6bac5","article-title":"Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection","volume":"87","author":"Fehr","year":"2009","unstructured":"15.\tFehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation. 2009;87(12):1837-1841.","journal-title":"Transplantation"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/ndt\/16.10.2058","article-title":"Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection.","volume":"16","author":"Regele","year":"2001","unstructured":"16.\tRegele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant. 2001;16: 2058-2066,","journal-title":"Nephrol Dial Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"issue":"2","key":"ref16","article-title":"Chronic antibody mediated rejection of renal allograft \u2013 efficacy of combined treatment with plasma exchanges, intravenous immunoglobulin and rituximab (one center experience).","volume":"6","author":"Stolyarevich","year":"2016","unstructured":"17.\tStolyarevich ES, Artyukhina LA, Zakharova EV, Tomilina NA. Chronic antibody mediated rejection of renal allograft \u2013 efficacy of combined treatment with plasma exchanges, intravenous immunoglobulin and rituximab (one center experience). J Nephrol Ther 2016;6(2).","journal-title":"J Nephrol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/2161-0959","issn-type":"print"},{"issue":"4","key":"ref17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","unstructured":"18.\tMoreso F, Crespo M, Ruiz JC, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018;18(4):927-935.","journal-title":"Am J Transplant"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","unstructured":"19.\tChoi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381-2389.","journal-title":"Am J Transplant"},{"issue":"11","key":"ref19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","article-title":"IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up","volume":"25","author":"Billing","year":"2012","unstructured":"20.\tBilling H, Rieger S, Susal C, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int. 2012;25(11):1165-1173.","journal-title":"Transpl Int"},{"issue":"4","key":"ref20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria","volume":"77","author":"Redfield","year":"2016","unstructured":"21.\tRedfield RR, Ellis TM, Zhong W, et al. Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol. 2016;77(4):346-352.","journal-title":"Hum Immunol"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trre.2017.01.002","article-title":"A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection","volume":"31","author":"Macklin","year":"2017","unstructured":"22.\tMacklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. Transplant Rev (Orlando). 2017;31(2):87-95.","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/bmb\/ldv013","article-title":"Kidney transplantation in highly sensitized patients","volume":"114","author":"Jordan","year":"2015","unstructured":"23.\tJordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull. 2015;114(1):113-125.","journal-title":"Br Med Bull"},{"issue":"12","key":"ref23","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","unstructured":"24.\tJordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256-3262.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"ref24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","unstructured":"25.\tLefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9(5):1099-1107.","journal-title":"Am J Transplant"},{"issue":"1","key":"ref25","first-page":"46","article-title":"Antibody-mediated rejection: a review.","volume":"17","author":"Garces","year":"2017","unstructured":"26.\tGarces JC, Giusti S, Staffeld-Coit C, Bohorquez H, Cohen AJ, Loss GE. Antibody-mediated rejection: a review. Ochsner J. 2017;17(1):46-55.","journal-title":"Ochsner J","ISSN":"https:\/\/id.crossref.org\/issn\/1524-5012","issn-type":"print"},{"issue":"4","key":"ref26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/tri.13111","article-title":"Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation","volume":"31","author":"Muller","year":"2018","unstructured":"27.\tMuller YD, Ghaleb N, Rotman S, et al. Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation. Transpl Int. 2018;31(4):451-455.","journal-title":"Transpl Int"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","unstructured":"28.\tSautenet B, Blancho G, B\u00fcchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016; 100 (2): 391-399.","journal-title":"Transplantation"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1111\/j.1600-6143.2009.02836.x","article-title":"The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy","volume":"9","author":"Haririan","year":"2009","unstructured":"29.\tHaririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant. 2009;9(12):2758-2767.","journal-title":"Am J Transplant"},{"issue":"12","key":"ref29","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1097\/TXD.0000000000000746","article-title":"Rituximab and monitoring strategies for late antibody-mediated rejection after kidney transplantation.","volume":"3","author":"Parajuli","year":"2017","unstructured":"30.\tParajuli S, Mandelbrot DA, Muth B, et al. Rituximab and monitoring strategies for late antibody-mediated rejection after kidney transplantation. Transplant Direct. 2017;3(12):e227.","journal-title":"Transplant Direct"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","unstructured":"31.\tKulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant. 2017;17(3):682-691.","journal-title":"Am J Transplant"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1745-6215-15-107","article-title":"Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial","volume":"15","author":"Eskandary","year":"2014","unstructured":"32.\tEskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15:107.","journal-title":"Trials"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T04:09:58Z","timestamp":1550635798000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/forms\/ectrxcontentshow.php?doi_id=10.6002\/ect.MESOT2018.O58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2018.o58","relation":{},"ISSN":["1304-0855"],"issn-type":[{"value":"1304-0855","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}